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Atopic dermatitis (AD) is a common chronic skin
disease characterized by recurrent skin inflammation
and a weak skin barrier, and is known to be a
precursor to other allergic diseases such as asthma.
AD affects up to 25% of children worldwide
and the incidence continues to rise. There is still
uncertainty about the optimal treatment strategy
in terms of choice of treatment, potency, duration
and frequency. This study aims to develop a
computational method to design optimal treatment
strategies for the clinically recommended ‘proactive
therapy’ for AD. Proactive therapy aims to prevent
recurrent flares once the disease has been brought
under initial control. Typically, this is done by using
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an anti-inflammatory treatment such as a potent topical corticosteroid intensively for a few
weeks to ‘get control’, followed by intermittent weekly treatment to suppress subclinical
inflammation to ‘keep control’. Using a hybrid mathematical model of AD pathogenesis
that we recently proposed, we computationally derived the optimal treatment strategies for
individual virtual patient cohorts, by recursively solving optimal control problems using a
differential evolution algorithm. Our simulation results suggest that such an approach can
inform the design of optimal individualized treatment schedules that include application of
topical corticosteroids and emollients, based on the disease status of patients observed on
their weekly hospital visits. We demonstrate the potential and the gaps of our approach to
be applied to clinical settings.
This article is part of the themed issue ‘Mathematical methods in medicine: neuroscience,
cardiology and pathology’.
1. Introduction
Atopic dermatitis (AD) is a chronic inflammatory disease, characterized by recurrent skin
inflammation and a defective, permeable skin barrier, that is considered to be caused by complex
interactions of genetic and environmental risk factors [1,2]. AD affects up to 25% of children
worldwide and has associated socioeconomic burdens [3]. AD is associated with constant itching
that may result in chronic sleep loss, and the resultant scratching can cause bleeding and skin
infections. The current mainstay of AD treatment is to control the AD symptoms by topical
application of corticosteroids or calcineurin inhibitors to reduce the inflammation, in addition
to application of emollients to improve the barrier integrity [1,3,4]. However, only 24% of AD
patients and carers believe that they adequately manage the symptoms by the current main
treatments [5]. This is partly because clear guidance and consensus for effective treatment
strategies in terms of frequency, duration and potency are yet to be fully established [2,3,6],
while patients are often advised to minimize the use of corticosteroids because of a fear of skin
thinning [7].
As a result of the complex underlying mechanisms of AD pathogenesis, AD patients
demonstrate a wide spectrum of clinical phenotypes thereby greatly benefitting from
personalized treatment [8]. Recently, long-term management of AD focuses on prevention of
flares by the so-called ‘proactive therapy’ [9,10]. Following initial induction of remission to ‘get
control’, proactive therapy aims to ‘keep control’ by preventing AD flares (inflammation) and
achieving skin barrier stabilization. This is achieved by intermittent and scheduled use of low-
dose topical corticosteroids or calcineurin inhibitors to the areas of the body that frequently
have recurrent flares, even in the absence of the flares. Ideally, effective treatment schedules
for proactive therapy can be tailored to each patient, based on the patient’s information, such
as genetic risk factors, how the symptoms have evolved and the responses to the treatments.
This paper investigates the potential of a computational method to inform the design of such
personalized effective treatment schedules for proactive therapy, in terms of frequency, duration
and potency.
We recently proposed a mathematical model of AD pathogenesis, as an in silico and
quantitative framework that coherently explains underlying mechanisms of common AD
phenotypes [11]. The model is a system-level representation of the complex and dynamic
interplays between immune responses, skin barrier function and environmental triggers that
determine the AD pathogenesis; specifically how AD flares start and how AD symptoms
exacerbate. Our model simulations reproduced several sets of experimental and clinical results,
providing plausible mechanistic and quantitative explanations for dynamic mechanisms behind
onset, progression and prevention of AD.
In this study, we extend this experimentally validated mathematical model of AD pathogenesis
and propose a new model of treatment effects on AD pathogenesis. We then use the mathematical
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Figure 1. Mathematical model of treatment effects on AD pathogenesis. (a) A model schematic and (b) a perfect reversible
switch for the AD flare triggered by infiltrated pathogens. The italics denote the model variables.
model to computationally design the personalized optimal treatment schedules for proactive
therapy by solving the optimal control problems recursively using a differential evolution (DE)
algorithm [12,13], which is an efficient global optimization technique to solve our non-convex
optimization problem.
2. Mathematical model of treatment effects on atopic dermatitis pathogenesis
We consider a mathematical model of treatment effects on AD pathogenesis (figure 1a) obtained
by incorporating the dynamic effects of treatments in the previous mathematical model of AD
pathogenesis [11]. The proposed model is described by a set of three differential equations:
P˙(t) = Penv κP1 + γBB(t)
−
(
αI
R(t)
1 + β1C(t)
+ δP
)
P(t), (2.1)
B˙(t) = κB(1 − B(t))
(1 + γR(R(t)/(1 + β2C(t))))(1 + γG(G(t)/(1 + β3C(t))))
+ E(t) − δBK(t)B(t) (2.2)
and D˙(t) = κD R(t)1 + β4C(t)
− δDD(t), (2.3)
where P(t) is the amount of infiltrated environmental stressors, such as pathogens, that trigger the
skin inflammation (AD flare) through activation of innate immune receptors (R(t)), B(t) denotes
the strength of skin barrier integrity andD(t) denotes the level of inflammation markers, including
pro-inflammatory cytokines (such as TSLP or IL33) and activated dendritic cells. A triple of the
state variables, (P(t),B(t),D(t)), represents the patient’s disease status described by the levels of
infection, barrier defects and inflammation. The variables E(t) and C(t), respectively, represent the
potency of emollients and corticosteroids that are applied to achieve skin barrier stabilization and
to prevent infection and inflammation. The parameters β1, β2, β3 and β4 represent the relative
effects of corticosteroids on the relevant processes (table 1). Other model parameters and their
nominal parameter values are taken from [11] (table 2).
The proposed model describes the effects of the treatments on AD pathogenesis in a
simple form, rather than explicitly incorporating the fine details of the complex molecular
and cellular processes. The infiltrated stressors or pathogens, P(t), increase by the penetration
of environmental stressors, Penv, through the barrier, B(t). P is eradicated by innate immune
responses triggered by inflammation (R(t)) and is also naturally degraded. Topical application
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of corticosteroids (C(t)) provides an anti-inflammatory action [4], resulting in a reduced
antimicrobial protein (AMP) expression for eradication of pathogens [14]. The production of
B(t) is described by a phenomenological representation of its capacity to self-restore the nominal
barrier integrity (B= 1) following its disruption, and is compromised by innate immune responses
triggered by inflammation and by cytokines produced by differentiated Th2 cells (where the
differentiation is controlled by the master transcription regulator Gata 3, G(t)). Topical application
of corticosteroids reduces both inflammation and release of cytokines [3,15], resulting in improved
skin barrier function [16]. Application of emollients enhances skin barrier integrity [3,4], helping
reduce AD symptoms [17]. The degradation of the barrier occurs as a result of desquamation
mediated by active kallikreins, K(t). The level of inflammation markers, D(t), increases while
inflammation (R(t)) persists and degrades naturally.
The main aim of the proactive therapy is to prevent AD flares that are assumed to occur
as a result of activation of the innate immune receptors. We model the AD flare by a perfect
reversible switch between the off- and on-states (R=Roff and Ron) with P+ and P− denoting,
respectively, the activation and inactivation thresholds for the infiltrated stressors (pathogens)
that are recognized by the innate immune receptors (figure 1b) [11]. An AD flare occurs when
the level of the stressors increases above P+, and stops when it decreases below P−. A similar
switching behaviour is assumed for K [11].
In our study, we consider moderate to severe AD patients, who could benefit from proactive
therapy for flare prevention and skin barrier stabilization. The severity of the AD symptoms is
characterized in our model by two model parameters, κP and αI, that correspond to the level of
the genetic risk factors: mutations in the FLG gene (κP) and a dysregulated expression of innate
immune system components (αI) including regulators of antimicrobial peptide expression (e.g.
TLRs and NF-κB) [11,18]. A lower αI indicates dysfunctional immune responses and a diminished
capacity to eradicate the infiltrating pathogens, and a higher κP results in a higher skin barrier
permeability leading to increased infiltration of stressors that can cause the recurrence of AD
flares. To simulate these moderate to severe AD patients, we pick the values of (αI, κP) from the
parameter region for which a unique pathological steady state exists that corresponds to the high
level of stressors leading to a persistent AD flare and completely damaged skin barrier. We also
assume Roff = 1 and Koff = 1 to model the effects of subclinical inflammation in non-lesional skin
of severe AD patients [10], and G(t) = 1 corresponding to systemic Th2 sensitization due to the
persistent AD flare [11].
3. Optimal control problem formulation
Using the proposed model, we computationally design optimal treatment strategies for proactive
therapy with a combination of emollients and corticosteroids. The proactive therapy consists of
two phases: an ‘induction of remission’ phase where we aim to suppress the clinical inflammation,
followed by a ‘maintenance of remission’ phase where we apply intermittent but scheduled
treatment to prevent the recurrence of the AD flare [9,10]. We refer to the two phases as
‘induction phase’ and ‘maintenance phase’ hereafter. The induction phase aims to ‘get control’,
and the maintenance phase aims to ‘keep control’ [10]. To comply with the current clinical
recommendations [3,19], we assume that emollients are applied constantly throughout both
phases at a low level, E¯, which is insufficient to achieve the remission by itself for moderate
to severe AD patients [20]. We, therefore, design the optimal schedules for application of
corticosteroids that can induce and maintain the remission. We consider the on–off treatment at
discrete times, reflecting the daily application or non-application of corticosteroids with different
potencies (figure 2a).
We formulate the problem as finding optimal treatment strategies that minimize the duration
and potency of the treatments that effectively move the state variables from the initial steady
state to the specified target state, while the dynamics of the state variables is determined by
our model (figure 2b). The target state is defined by a target level of P(t) that does not lead
to recurrence of an AD flare (figure 1b), as the proactive therapy aims to prevent the AD flare.
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Figure 2. Optimal control problem formulation to design treatment strategies for proactive therapy for AD. The whole period
consists of the induction phase (red) andmaintenance phase (blue). (a) An example dynamics of a state variable (P(t)) with on–
off treatment of corticosteroids (C(t)) of different potencies at discrete times, in addition to constant application of emollients
(E(t)) of a fixed potency E¯. (b) An example trajectory of a projection of a patient’s states, (P, D), when the optimal treatment
strategy is applied. The states move from the initial state ((P0, D0), red circle) towards the target level, Pˆr, of the induction
phase (red vertical line), and then to the target level, Pˆm, of the maintenance phase (blue vertical line). The state B is omitted
in the figure. (c) The recursive optimal control problem to be solved. The optimal treatment strategy for each cycle (either for
the duration of Tr or Tm) is determined by predicting the optimal evolution of the state variables (dashed lines) based on the
measurement of the states at the beginning of the period (circles). The actual evolution of the state (solid lines) can be different
from the prediction, for example if the calculated optimal treatment strategy is not applied.
The objective function, J, is described by J = k1J1 + k2J2 + k3J3 + k4J4, where J1 is the penalty for
the treatment duration, corresponding to the patients’ burden to apply the treatments, J2 is the
penalty for the total amount of the treatment applied (duration × strength), representing the
financial cost as well as the risk of side effects due to the excessive use of corticosteroids, J3
is the penalty for the final state to be deviated from the target state and J4 is the penalty for
the trajectory to be deviated from the target state. The functions J1, J2, J3 and J4 are defined for the
induction and maintenance phases as shown below. We assume k3 = k4 (the coefficients for the
penalty on the deviation from the target state) for simplicity.
(a) Induction of remission phase
In the induction phase, we assume that corticosteroids are constantly applied during the
calculated optimal duration, Tr. The optimal problem to be solved is formulated so as to
find a pair of values, (Tr, C¯), where Tr is the duration of the induction phase and C¯ is the
potency of corticosteroid to be constantly applied during this phase to minimize the objective
function under the constraints 0 ≤ Tr ≤ Tmaxr and 0 ≤ C¯≤Cmax. We set the target level, Pˆr,
to be smaller than P− where the AD flare ceases. The objective function for the induction
phase consists of J1 = (Tr/Tmaxr )2, J2 = (Tr/Tmaxr )(C¯/Cmax)2, J3 = Φr(P(Tr)) + (1 − P(Tr)/Pˆr)2 and
J4 =
∫Tr
0 (P(τ ) − Pˆr)2 dτ/
∫Tr
0 P(τ )
2 dτ . Φr(P(Tr)) is a non-convex function that penalizes the
failure to achieve remission and takes the values of 100 + 0.1(P(Tr) − P−) if P(Tr) > P− and
0 otherwise.
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(b) Maintenance of remission phase
Once the remission is induced, the proactive therapy proceeds to the maintenance phase, where
corticosteroids are applied intermittently to prevent the recurrence of AD flares. We design the
optimal treatment schedule for a week, based on the measurement of the state variables at the
beginning of the week, and repeat the weekly cycle (figure 2c). This scenario corresponds to
weekly hospital visits of the patients where clinicians evaluate the disease state and plan the
treatment strategy until the next visit.
For the ith cycle of the maintenance phase, we calculate the optimal treatment strategy (TiC, C¯
i)
that minimizes the objective function, under the constraints on the duration of corticosteroid
application, 0 ≤ TiC ≤ Tm = 7 days, and its potency 0 ≤ C¯i ≤Cimax. For the whole duration of
the maintenance phase, we set the target level, Pˆm, that is smaller than P+ to avoid the
recurrence of the AD flare (figure 1b). In the next section, we investigate the effects of
the choice of Pˆm on the calculated optimal treatment strategies. The objective function for
the ith maintenance cycle consists of J1 = (TiC/Tm)2, J2 = (C¯i/Cimax)2(TiC/Tm), J3 = Φm(P(Tr +
iTm)) + (1 − P(Tr + iTm)/Pˆm)2 and J4 =
∫Tr+iTm
Tr+(i−1)Tm (P(τ ) − Pˆm)2 dτ/
∫Tr+iTm
Tr+(i−1)Tm P
2(τ ) dτ . A non-
convex function, Φm(P(Tr + iTm)), represents the penalty on the re-occurrence of an AD flare
during the maintenance phase, and takes the values of 100 + 0.1(P(Tr + iTm) − P−) if both
P(Tr + iTm) > P− and R(t) =Ron are satisfied, and 0 otherwise.
4. Computational identification of optimal treatment schedules for moderate
to severe atopic dermatitis patients
We used DE to solve the optimal control problem formulated above, for different scenarios, to
test the applicability of our approach. The nominal values used for the simulations for moderate
to severe AD patient cohorts, such as the target levels and the constraints on the strength and
duration of treatments, are summarized in table 1. We first confirmed that the optimal treatment
strategy calculated using the nominal parameter values suggests a length of the induction phase,
Tr, that is clinically relevant (less than or equal to four weeks [21]). Indeed, the optimal induction
period was calculated to be Tr = 19 days, while the AD flare stopped within the first 3 days
(figure 3a). We also confirmed by global sensitivity analysis that this calculated optimal strategy
is robust to changes of the model parameters and choice of the weighting coefficients for the
objective function (electronic supplementary material, figures S1 and S2).
(a) Effects of the choice of the maintenance target level
We investigated the effects of the choice of the target level during the maintenance phase on the
calculated optimal treatment strategies (figure 3).
In the nominal case with the nominal parameter values, we set the maintenance target
level to be Pˆm = 26, which is lower than the deactivation threshold (P− = 26.6) but higher than
the induction target level (Pˆr = 24). The calculated optimal maintenance treatment (figure 3a)
demonstrates that intermittent application of corticosteroids by 3 days per week could achieve
the maintenance without recurrence of the AD flare for the whole duration of the maintenance
phase investigated (eight weeks).
When the maintenance target is chosen to be closer to the activation threshold (P+ = 40),
for example Pˆm = 30, the calculated optimal treatment strategy suggests the application of
corticosteroids by 1 day per week to maintain the remission (figure 3b). This higher target level
is much easier to be maintained with a smaller amount of corticosteroids. However, the resulting
state corresponds to a lower barrier integrity with a higher level of infiltrated stressors, compared
with the nominal scenario (figure 3a), due to a smaller amount of corticosteroid applied. This
worsening of the state may make patients more vulnerable to an increased level of environmental
stressors due to random or natural fluctuations that can retrigger an AD flare.
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Figure 3. Effects of the choice of themaintenance target level (blue dotted lines) on the optimal treatment strategies calculated
and the resulting dynamics of the system. Themaintenance target level is set to be (a) Pˆm = 26 (the nominal value), (b) Pˆm =
30 and (c) Pˆm = 20, while the induction target level (red vertical lines) is set to be the same (Pˆr = 24) for all the scenarios. The
dynamics during the induction phase and that during themaintenance phase are shown in red and blue, respectively. Remission
is achieved when the level of the stressors is decreased below P−, and the AD flare reoccurs when it increases above P+. The
induction phase continues even after the AD flare ceases, and tries to bring the state towards the target level.
On the contrary, when the maintenance target is chosen to be further lower than P−, for
example Pˆm = 20, the optimal treatment strategy requires an increased amount of corticosteroids,
with application of more potent corticosteroids for 6 days per week, to achieve a very low
target value (figure 3c). While the calculated optimal treatment strategy can successfully prevent
recurrence of inflammation, this strategy is not desired due to the high amount of corticosteroids
applied in total (2.7-fold increase from the nominal case).
These results suggest the importance of the choice of the maintenance target level, Pˆm,
as a design criterion for optimal treatment strategies. We decided to use Pˆm = 26 for further
simulations, as it ensures the successful maintenance of remission without the need of excessive
treatment amount during the maintenance phase and it may correspond to the clinically
suggested so-called weekend therapy.
We also investigated the effects of choice of the induction target, Pˆr (figure not shown).
Decrease of Pˆr from our nominal value of Pˆr = 24 resulted in an optimal strategy that requires
an increased amount of corticosteroid (in both the potency and application time) during the
induction phase, but did not affect the strategy during the maintenance phase.
(b) Stratification of patient cohorts
To demonstrate that our approach is applicable to different patient cohorts, we computationally
obtained the optimal treatment strategies for different values of two model parameters, (κP, αI),
that can specify patient cohorts by their strengths of the two main genetic risk factors, mutations
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Table 1. Description of simulation parameters and their nominal values.
symbol name nominal value
β1 corticosteroid-mediated rate of reduction of AMP expression 0.005
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
β2 corticosteroid-mediated rate of reduction in barrier damage 10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
β3 corticosteroid-mediated rate of reduction of Th2 cytokine production 10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
β4 corticosteroid-mediated rate of reduction of dendritic cell maturation 10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
E¯ strength of emollients applied 0.04
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cmax maximum strength of corticosteroids during the remission phase 50
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cimax maximum strength of corticosteroids during the ith maintenance cycle 50. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tmaxr maximum duration of the induction phase 8 (weeks). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tm duration of each maintenance cycle 1 (week)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
k1 penalty weight for treatment duration 0.5
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
k2 penalty weight for total amount of treatment 1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
k3 penalty weight for deviation of the final level of P from the target level 10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
k4 penalty weight for deviation of the trajectories of P from the target level 10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pˆr target level of P during the induction phase 24
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pˆm target level of P during the maintenance phase 26
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
in the FLG gene (κP) and a dysregulated expression of innate immune system components (αI).
The objective functions and target states were the same as the nominal case.
Specifically, we investigated three patient cohorts: the nominal patient cohorts with (κP, αI) =
(0.85, 0.05) (figure 3a), those with even more dysfunctional immune responses described
by (κP, αI) = (0.85, 0.04) (figure 4a) and (κP, αI) = (0.85, 0.03) (figure 4b), and those with even
more compromised barrier integrity described by (κP, αI) = (0.9, 0.05) (figure 4c) and (κP, αI) =
(0.95, 0.05) (figure 4d). All the parameters, except for κP and αI, were set to be the nominal values
(tables 1 and 2).
For the case with (κP, αI) = (0.85, 0.04) (figure 4a), the calculated optimal treatment strategy
was successful in achieving remission and preventing AD flares for eight consecutive weeks, by
an induction treatment of 20 days followed by 3 days per week maintenance treatment. However,
it requires a higher amount of corticosteroids (48% increase for the induction phase and 3.3%
increase for the maintenance phase) of a higher potency, compared to the nominal case (figure 3a),
to combat the higher initial stressor load. When the risk factor of dysfunctional immune responses
becomes even stronger, as for the case with (κP, αI) = (0.85, 0.03) (figure 4b), the calculated optimal
treatment schedule failed to achieve remission, leading to sustained or unresolved AD symptoms
with a low barrier integrity. Indeed, the ‘maintenance’ therapy we computationally calculated
after 14 days of the ‘failed’ induction of remission suggests a continuous use of corticosteroids,
meaning that these virtual patients will require constant, rather than intermittent, application of
corticosteroids (figure 4b).
For the cohorts with an increased barrier permeability (κP = 0.9), an increased amount of
corticosteroid (by 54.7%) is required during the maintenance phase (figure 4c), compared to the
nominal cohort with the same αI = 0.05. Further increase in the barrier permeability (κP = 0.95)
led to failure in inducing remission and the optimal strategy suggests to continue the constant
application of corticosteroids (figure 4d). Synergistic effects of the two risk factors, by increasing κP
and decreasing αI simultaneously ((κP, αI) = (0.9, 0.04), figure not shown), resulted in an optimal
strategy with a 5.8-fold increase in the total amount of corticosteroid (2.35-fold in the induction
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Figure 4. Calculated optimal treatment strategies for different patient cohorts with dysfunctional immune responses:
(a) (κP,αI)= (0.85, 0.04) and (b) (κP,αI)= (0.85, 0.03); and compromised barrier integrity: (c) (κP,αI)= (0.9, 0.05) and
(d) (κP,αI)= (0.95, 0.05). The dynamics during the induction phase starting from the initial state (red circles) is shown in red,
and that for the maintenance phase is in blue.
phase and 11.3-fold in the maintenance phase), compared to the nominal cohort. However, the
optimal strategy still could not achieve remission.
These results suggest that our approach is applicable to different virtual patient cohorts, and
that it could help stratify the virtual patients into those who would benefit from the calculated
optimal treatment strategies, and those who would require additional or stronger treatments,
such as systemic treatment, to achieve remission. Our results also demonstrate how the treatment
efforts scale with the level of the two common AD risk factors. It will be interesting to compare
the computational predictions with the patients’ data that relate the severity of the patients’
symptoms to the required treatments and the actual treatments prescribed. Evaluation of how
the treatment efforts scale with the initial disease severity before the start of treatments in the
clinic is an interesting future research topic.
(c) Effects of poor adherence to suggested optimal treatment schedule
So far, we assumed that the patients follow the calculated optimal treatment schedule. However,
AD patients do not necessarily always follow the treatment guidelines. This problem of poor
adherence to treatment could have negative effects on long-term treatment of AD [22,23]. Using
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Table 2. Description of model parameters and their nominal values.
symbol name nominal value
Penv environmental stress load 95 (mg ml−1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
γB barrier-mediated inhibition of pathogen infiltration 1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
κP nominal skin permeability 0.85 (day−1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
αI rate of pathogen eradication by innate immune responses 0.05 (day−1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
δP basal pathogen death rate 1.6 (day−1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
κB barrier production rate 0.5 (day−1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
γR innate immunity-mediated inhibition of barrier production 10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
δB rate of kallikrein-dependent barrier degradation 0.1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
γG adaptive immunity-mediated inhibition of barrier production 1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
κD rate of DC activation by receptors 4 cells (ml × day)−1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
δD rate of DC degradation 0.5 (day−1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
P− receptor inactivation threshold 26.6 (mg ml−1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
P+ receptor activation threshold 40 (mg ml−1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Roff receptor-off level 1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ron receptor-on level 16.7
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
our proposed approach, we investigated the effects of poor adherence to the calculated optimal
treatment schedule, particularly how the future optimal treatment schedule and the evolution of
the disease state are affected.
Consider the case where the virtual patients do not complete the calculated optimal induction
phase and stop using corticosteroids after 5 days when the AD flare disappears. This scenario can
occur, for example, due to corticosteroid phobia. If they continue their daily emollient treatment
(figure 5a), the optimal strategy in the subsequent weeks suggests the use of an increased amount
of corticosteroid, with a 1.4-fold more potent corticosteroid for a longer period (by 1 day) during
the first maintenance cycle, compared with the nominal case. The effect of non-adherence is not
predicted to be dramatic, possibly because the AD flare ceased already within the first 5 days
of corticosteroid use. However, if the virtual patients also stop the daily emollient treatment
(figure 5b), we observe the recurrence of an AD flare with a severe worsening of the symptoms
(a sharp decrease in B and a dramatic increase in P and D). As a result, the calculated optimal
strategy in the subsequent cycle suggests the use of a more potent corticosteroid (by 1.4-fold) than
that applied during the induction phase, for 5 days. This corresponds to a prolonged induction
phase with a more potent corticosteroid. If we prolong the maintenance cycle to 20 days from
7 days, the calculated optimal strategy suggests the application of a corticosteroid of 10% more
potent than that used for the induction phase, for an extra duration of 10 days (figure not shown).
These computational predictions suggest the benefits of continual use of emollients in reducing
AD symptoms, as shown in [3].
Another scenario to be considered is the non-adherence during the maintenance phase,
following the successful completion of the induction phase. When the virtual patients stop their
daily application of emollients for the first three maintenance cycles (figure 5c), it results in an
immediate worsening of the symptoms (a decrease in B). The calculated optimal strategy suggests
application of more potent corticosteroids (by 1.4-fold) than the nominal case for 3 days per
week in the subsequent three weeks to maintain the remission. When they also stop applying
corticosteroids during these three weeks (figure 5d), a severe worsening of the symptoms (a sharp
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Figure 5. Effects of poor adherence to the calculated optimal treatment strategies. Non-adherence to the suggested
corticosteroid treatment after 5 days in the induction phase, with continual use of emollients (a) and without use of emollients
(b). Non-adherence to the suggested corticosteroid treatment during the maintenance phase, without emollient application
for the first three cycles (c), and without both corticosteroid and emollient application for the first three cycles (d) and four
cycles (e). Green lines represent the period during the non-adherence, and the dotted lines on the right column demonstrate
the optimal strategy calculated for the nominal case where patients adhere to the suggested optimal strategy.
decrease in B and a dramatic increase in P and D) is observed. The calculated optimal strategy
then suggests application of an increased amount of corticosteroid (1.5-fold more potent for two
more days) than the nominal case to maintain the remission in the subsequent weeks. If they miss
the treatments for four weeks (figure 5e), the AD flare reoccurs and the optimal strategy suggests
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the use of a much more potent corticosteroid (by 1.35-fold) than that used during the induction
phase, for the duration of 5 days.
5. Discussion
In this paper, we proposed a computational method to inform the design of patient-specific
optimal treatment strategies for moderate to severe AD patients who require constant treatment
for stabilization of their AD symptoms. Our proposed framework solves optimal control
problems recursively to design treatment schedules for proactive therapy that aims to prevent
AD flares and to achieve skin barrier stabilization. The proactive therapy consists of intermittent
and scheduled use of low-dose corticosteroids, in addition to a constant application of emollients,
once initial induction of remission has been achieved. The objective functions to be minimized
correspond to the penalties on the duration and the potency of the treatments applied, as well as
the deviation from the target states we specify.
One of the main difficulties in formulating an optimal control problem is to identify
appropriate objective functions. Here, we systematically explored different possible target levels
for the clinically relevant variables to be controlled (P) and found the most adequate maintenance
target level (figure 3), which we used to derive robust treatment strategies even with poor
adherence (figure 5), for our nominal patient cohorts and for patient cohorts with severer genetic
risk factors (figure 4). These results suggest the importance of choosing appropriate target states
to successfully maintain remission, and that our proposed mathematical framework can be used
to investigate the effects of poor adherence to the optimal treatment strategies systematically.
We could also identify those virtual patient cohorts that would require stronger treatments, with
even higher doses or additional pharmacological substances such as antibiotics, phototherapy
or systemic immunosuppressant treatment to achieve adequate disease control (figure 4). We
evaluated the sensitivity of our results to the changes in the values of k1, k2, k3 and k4, and the
model parameters, and confirmed that the optimal strategies calculated for the nominal case are
robust (electronic supplementary material, figures S1 and S2).
Our systematic and computational approach could be effective in informing the design
of personalized optimal treatment strategies, and help to solve the issues with the current
lack of a clear guidance and consensus for effective treatment strategies, and to minimize
the potential side effects of long-term use of corticosteroids. Moderate to severe AD patients
require repeated treatment to stabilize their pathological state that would naturally remain
unresolved if treatment is not applied. In addition, moderate to severe AD patients usually
require a combination of treatments (such as corticosteroids and emollients) to be applied to
achieve successful maintenance of remission in two phases (induction and maintenance phases).
Accordingly, designing the optimal treatment strategies to stabilize the AD symptoms for these
patients may benefit from an advanced optimization technique such as the one proposed in this
paper.
In this paper, we computationally obtained the optimal treatment strategy by recursively
solving the optimal control problems. The proposed computational framework could be easily
extended to the application of model predictive control (MPC), which uses the measured states of
the system to predict and optimize the control input that minimizes the objective function over a
future time horizon [24]. MPC has been already successfully applied to design treatment profiles
for diabetes [25,26], prostate cancer [27] and leukaemia [28,29]. Application of MPC, i.e. inclusion
of the receding horizon, will allow us to obtain smoother graded therapy, as it will enable us to
find the optimal treatment schedule that does not necessarily achieve the target level within each
maintenance cycle but achieves it gradually over a longer period.
Our simulation results in this paper show that poor adherence to the suggested optimal
treatment schedule inevitably leads to higher treatment doses in subsequent cycles. This indicates
a potential benefit of using our approach under more realistic clinical scenarios to provide a
theoretical argument to recommend patients to adhere to the suggested treatment strategies. Our
results are also consistent with the current clinical recommendations, for example, the weekend
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therapy with application of corticosteroids for two consecutive days per week, in addition to
the daily application of emollients. Our investigation on the effects of the AD flare that occurs
during maintenance therapy demonstrated that resuming continuous use of a much stronger
corticosteroid can successfully achieve remission but result in an increase in the total amount
of corticosteroids applied. As an important next step, we need to compare the computationally
obtained treatment strategies with treatment options that are currently used in the clinical setting.
We also need to develop robust ways to identify the simulation parameters and the model
parameters from each patient’s clinical data such as initial skin thickness and pattern of eczema,
in order to effectively calculate the optimal treatment strategies. If the temporal data of patients
become available, the information on the discrepancy between the measured values and the
model prediction will be used to identify the model parameters online. The approach we
proposed in this paper could be a first step towards designing personalized effective treatment
strategies for prevention, and adequate control, of AD symptoms. Exploring the personalized
optimal treatment strategies in the clinical setting would be challenging if we do not apply a
systematic and computational approach, because of the combinatorial explosion of treatment
types, durations, potencies and each patient’s information. As the model was developed based
on the understanding of the pathological mechanisms, the obtained treatment strategies could
be readily interpreted and the framework is applicable to different patient cohorts and different
scenarios. For example, it will help to identify a way to reduce the frequency of clinic visits
by placing control back in the hands of parents and children, evaluate the effects of reduced
visits and whether we can still achieve the optimal treatment strategies by monthly or bimonthly
clinical visits.
This paper demonstrated the proof of concept of the computational design of optimal
treatment strategies, using a mathematical model that describes the treatment effects in a simple
form. We will further investigate the appropriateness of the model description of the treatment
effects, using dynamic data of AD patients after application of corticosteroids and emollients.
6. Material and methods
All simulations were conducted using Matlab v. R2016a (The MathWorks, Inc., Natick, MA, USA).
We used ode45 for the numerical integration of the system and events location functionality of
Matlab to identify the switching boundaries of the hybrid system. We identified the optimal
treatment strategy for the induction phase by applying a DE algorithm with 1000 generations.
Starting from 30 randomly chosen initial vectors, (C¯,Tr), with 0 ≤ C¯≤ C¯max and 0 ≤ Tr ≤ Tmaxr ,
we found the optimal solution by evolving a population of 30 vectors at each generation, using
the mutation strategy DE/rand-to-best/1 [30] with a differential weight of 0.6 and recombination
with a crossover rate of 0.5. The same procedures were repeated for each maintenance cycle. The
global sensitivity analysis was conducted by simultaneously varying the values of the model
parameters or the weights for the objective functions from their nominal values by ±50% for 529
and 400 simulations, respectively.
Data accessibility. All the necessary pieces of information to reproduce this study are included in this paper and
its supplementary material available online.
Authors’ contributions. Y.H., E.D.-H., K.A. and R.J.T. conceived the research. P.C. and Y.H. conducted the numerical
simulations. P.C., E.D.-H., S.G.D., M.J.C., H.C.W. and R.J.T. analysed the data. All authors wrote the
manuscript.
Competing interests. The authors declare that they have no competing interests.
Funding. K.A. is supported by the Japan Society for the Promotion of Science (JSPS) Kakenhi grant no.
15H05707, and CREST, JST. R.J.T. acknowledges the partial support from EPSRC.
Acknowledgements. We acknowledge the fruitful discussion with Prof. Alan Irvine and Dr Gouhei Tanaka.
References
1. Weidinger S, Novak N. 2016 Atopic dermatitis. Lancet 387, 1109–1122. (doi:10.1016/
S0140-6736(15)00149-X)
 on May 30, 2017http://rsta.royalsocietypublishing.org/Downloaded from 
14
rsta.royalsocietypublishing.org
Phil.Trans.R.Soc.A375:20160285
.........................................................
2. Bieber T et al. 2016 Global Allergy Forum and 3rd Davos Declaration 2015: atopic
dermatitis/eczema: challenges and opportunities toward precision medicine. Allergy 71,
588–592. (doi:10.1111/all.12857)
3. Eichenfield LF et al. 2014 Guidelines of care for the management of atopic dermatitis. J. Am.
Acad. Dermatol. 71, 116–132. (doi:10.1016/j.jaad.2014.03.023)
4. Simpson EL. 2010 Atopic dermatitis: a review of topical treatment options. Curr. Med. Res.
Opin. 26, 633–640. (doi:10.1185/03007990903512156)
5. Zuberbier T et al. 2006 Patient perspectives on the management of atopic dermatitis. J. Allergy
Clin. Immunol. 118, 226–232. (doi:10.1016/j.jaci.2006.02.031)
6. Williams HC. 2005 Atopic dermatitis. N. Engl. J. Med. 352, 2314–2324. (doi:10.1056/
NEJMcp042803)
7. Cork MJ et al. 2009 Epidermal barrier dysfunction in atopic dermatitis. J. Invest. Dermatol. 129,
1892–1908. (doi:10.1038/jid.2009.133)
8. Bieber T. 2015 Personalized management of atopic dermatitis: beyond emollients and topical
steroids. In Personalized treatment options in dermatology, pp. 61–76. Berlin, Germany: Springer.
(doi:10.1007/978-3-662-45840-2).
9. Wollenberg A, Ehmann LM. 2012 Long term treatment concepts and proactive therapy for
atopic eczema. Ann. Dermatol. 24, 253–260. (doi:10.5021/ad.2012.24.3.253)
10. Tang TS, Bieber T, Williams HC. 2014 Are the concepts of induction of remission and treatment
of subclinical inflammation in atopic dermatitis clinically useful? J. Allergy Clin. Immunol. 133,
1615–1625. (doi:10.1016/j.jaci.2013.12.1079)
11. Domínguez-Hüttinger E, Christodoulides P, Miyauchi K, Irvine AD, Okada-Hatakeyama M,
Kubo M, Tanaka RJ. 2017 Mathematical modelling of atopic dermatitis reveals ‘double switch’
mechanisms underlying 4 common disease phenotypes. J. Allergy Clin. Immunol. 139, 31 433–
31 436. (doi:10.1016/j.jaci.2016.10.026)
12. Storn R, Price K. 1997 Differential evolution—a simple and efficient heuristic for global
optimization over continuous spaces. J. Glob. Optim. 11, 341–359. (doi:10.1023/A:10082028
21328)
13. Price KV, Storn RM, Lampinen JA. 2005 Differential evolution. Natural Computing Series.
Berlin, Germany: Springer. (doi:10.1007/3-540-31306-0)
14. Jensen JM et al. 2011 Differential suppression of epidermal antimicrobial protein expression
in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids. Exp.
Dermatol. 20, 783–788. (doi:10.1111/j.1600-0625.2011.01322.x)
15. Rozkova D, Horvath R, Bartunkova J, Spisek R. 2006 Glucocorticoids severely impair
differentiation and antigen presenting function of dendritic cells despite upregulation of
Toll-like receptors. Clin. Immunol. 120, 260–271. (doi:10.1016/j.clim.2006.04.567)
16. Jensen JM, Pfeiffer S, Witt M, Bräutigam M, Neumann C, Weichenthal M, Schwarz T,
Fölster-Holst R, Proksch E. 2009 Different effects of pimecrolimus and betamethasone on
the skin barrier in patients with atopic dermatitis. J. Allergy Clin. Immunol. 123, 1124–1133.
(doi:10.1016/j.jaci.2009.03.032)
17. Mason JM, Carr J, Buckley C, Hewitt S, Berry P, Taylor J, Cork MJ. 2013 Improved
emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-
after evaluation of a multifaceted educational support programme. BMC Dermatol. 13, 7.
(doi:10.1186/1471-5945-13-7)
18. Domínguez-Hüttinger E, Ono M, Barahona M, Tanaka RJ. 2013 Risk factor-dependent
dynamics of atopic dermatitis: modelling multi-scale regulation of epithelium homeostasis.
Interface Focus 3, 20120090. (doi:10.1098/rsfs.2012.0090)
19. Ring J et al. 2012 Guidelines for treatment of atopic eczema (atopic dermatitis). II. J. Eur. Acad.
Dermatol. Venereol. 26, 1176–1193. (doi:10.1111/j.1468-3083.2012.04636.x)
20. Ng SY, Begum S, Chong SY. 2016 Does order of application of emollient and topical
corticosteroids make a difference in the severity of atopic eczema in children? Pediatr.
Dermatol. 33, 160–164. (doi:10.1111/pde.12758)
21. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. 2011 Efficacy and tolerability of
proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema:
systematic review and meta-analysis of randomized controlled trials. Br. J. Dermatol. 164,
415–428. (doi:10.1111/j.1365-2133.2010.10030.x)
 on May 30, 2017http://rsta.royalsocietypublishing.org/Downloaded from 
15
rsta.royalsocietypublishing.org
Phil.Trans.R.Soc.A375:20160285
.........................................................
22. Aubert-Wastiaux H et al. 2011 Topical corticosteroid phobia in atopic dermatitis: a study
of its nature, origins and frequency. Br. J. Dermatol. 165, 808–814. (doi:10.1111/j.1365-2133.
2011.10449.x)
23. Ellis RM, Koch LH, McGuire E, Williams JV. 2011 Potential barriers to adherence in pediatric
dermatology. Pediatr. Dermatol. 28, 242–244. (doi:10.1111/j.1525-1470.2011.01493.x)
24. Camacho EF, Bordons C. 2007 Model predictive control. Advanced Textbooks in Control and
Signal Processing. London, UK: Springer. (doi:10.1007/978-0-85729-398-5).
25. Clarke WL, Anderson S, Breton M, Patek S, Kashmer L, Kovatchev B. 2009 Closed-loop
artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model
predictive control algorithm: the Virginia experience. J. Diabetes Sci. Technol. 3, 1031–1038.
(doi:10.1177/193229680900300506)
26. Hovorka R et al. 2010 Manual closed-loop insulin delivery in children and adolescents with
type 1 diabetes: a phase 2 randomised crossover trial. Lancet 375, 743–751. (doi:10.1016/
S0140-6736(09)61998-X)
27. Hirata Y, Azuma S, Aihara K. 2014 Model predictive control for optimally scheduling
intermittent androgen suppression of prostate cancer. Methods 67, 278–281. (doi:10.1016/j.
ymeth.2014.03.018)
28. Noble SL, Sherer E, Hannemann RE, Ramkrishna D, Vik T, Rundell AE. 2010 Using
adaptive model predictive control to customize maintenance therapy chemotherapeutic
dosing for childhood acute lymphoblastic leukemia. J. Theor. Biol. 264, 990–1002. (doi:10.1016/
j.jtbi.2010.01.031)
29. Jayachandran D, Rundell AE, Hannemann RE, Vik TA, Ramkrishna D. 2014 Optimal
chemotherapy for leukemia: a model-based strategy for individualized treatment. PLoS ONE
9, e109623. (doi:10.1371/journal.pone.0109623)
30. Yang M, Li C, Cai Z, Guan J. 2015 Differential evolution with auto-enhanced population
diversity. IEEE Trans. Cybern. 45, 302–315. (doi:10.1109/TCYB.2014.2339495)
 on May 30, 2017http://rsta.royalsocietypublishing.org/Downloaded from 
